Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Sarmishtha De"'
Autor:
George R. Stark, Neelesh Sharma, Goutham Narla, Sarmishtha De, Afshin Dowlati, John Pink, Katerina Gurova, Josephine Kam Tai Dermawan
Legends for Supplementary Tables 1,2 and Figures S1-S3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19440858800f57cbd3faf02074937d90
https://doi.org/10.1158/1535-7163.22501479
https://doi.org/10.1158/1535-7163.22501479
Autor:
George R. Stark, Neelesh Sharma, Goutham Narla, Sarmishtha De, Afshin Dowlati, John Pink, Katerina Gurova, Josephine Kam Tai Dermawan
Erlotinib is a tyrosine kinase inhibitor approved for the treatment of patients with advanced non–small cell lung cancer (NSCLC). In these patients, erlotinib prolongs survival but its benefit remains modest because many tumors express wild-type (w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ddaf68264ee91f07e1b7e103962e6cec
https://doi.org/10.1158/1535-7163.c.6536799.v1
https://doi.org/10.1158/1535-7163.c.6536799.v1
Autor:
George R. Stark, Afshin Dowlati, Gary Wildey, Claire J. Coleman, Daniel J. Lindner, Sarmishtha De
Supplementary Fig S1. CBL0137 in combination with cisplatin attenuates SCLC tumor growth. H82 SCLC cells, mixed with Matrigel (1:1), were inoculated subcutaneously into the flanks of NSG mice (n=8). Once the tumors reached â^¼50 mm3, the mice were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cd5bee1b3ca0892a474adad7850c391
https://doi.org/10.1158/0008-5472.22417206.v1
https://doi.org/10.1158/0008-5472.22417206.v1
Autor:
George R. Stark, Afshin Dowlati, Gary Wildey, Claire J. Coleman, Daniel J. Lindner, Sarmishtha De
Traditional treatments of small-cell lung cancer (SCLC) with cisplatin, a standard-of-care therapy, spare the tumor-initiating cells (TIC) that mediate drug resistance. Here we report a novel therapeutic strategy that preferentially targets TICs in S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0be846d6e9f0619530b7d5a499b28974
https://doi.org/10.1158/0008-5472.c.6509775
https://doi.org/10.1158/0008-5472.c.6509775
Publikováno v:
Curr Protoc
Forward genetics begins with a biological phenotype and attempts to identify genetic changes that influence that phenotype. These changes can be induced in a selected group of genes, for instance, by using libraries of cDNAs, shRNAs, CRISPR guide RNA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46a54e8ed22bf2c61fed147c0075beac
https://europepmc.org/articles/PMC8969887/
https://europepmc.org/articles/PMC8969887/
Publikováno v:
Proc Natl Acad Sci U S A
High expression of programmed death-ligand 1 (PD-L1) in cancer cells drives immune-independent, cell-intrinsic functions, leading to resistance to DNA-damaging therapies. We find that high expression of the ubiquitin E3 ligase FBXO22 sensitizes nonsm
Autor:
Yvonne Parker, Gary Wildey, George R. Stark, Daniel J. Lindner, Sarmishtha De, Afshin Dowlati
Publikováno v:
British Journal of Cancer
Small cell lung cancer (SCLC) is characterised by high relapse rates. Tumour-initiating cells (TICs) are responsible for drug resistance and recurrence of cancer. Rovalpituzumab tesirine (Rova-T), a potent humanised antibody–drug conjugate, selecti
Autor:
Afshin Dowlati, Sarmishtha De, Daniel J. Lindner, Claire J. Coleman, Gary Wildey, George Stark Stark
Publikováno v:
Cancer Research. 78:2396-2406
Traditional treatments of small-cell lung cancer (SCLC) with cisplatin, a standard-of-care therapy, spare the tumor-initiating cells (TIC) that mediate drug resistance. Here we report a novel therapeutic strategy that preferentially targets TICs in S
Autor:
Sarmishtha, De, Daniel J, Lindner, Claire J, Coleman, Gary, Wildey, Afshin, Dowlati, George R, Stark
Publikováno v:
Cancer research. 78(9)
Traditional treatments of small-cell lung cancer (SCLC) with cisplatin, a standard-of-care therapy, spare the tumor-initiating cells (TIC) that mediate drug resistance. Here we report a novel therapeutic strategy that preferentially targets TICs in S
Autor:
Goutham Narla, Katerina Gurova, Josephine K Dermawan, John J. Pink, Afshin Dowlati, Neelesh Sharma, Sarmishtha De, George Stark Stark
Publikováno v:
Molecular Cancer Therapeutics. 13:2203-2214
Erlotinib is a tyrosine kinase inhibitor approved for the treatment of patients with advanced non–small cell lung cancer (NSCLC). In these patients, erlotinib prolongs survival but its benefit remains modest because many tumors express wild-type (w